Reading room

Metabolic outcomes & safety.

Follow the clinical questions behind weight change: maintenance, lean tissue, sleep apnea, kidney and cardiovascular outcomes, liver histology and adverse-event signals. These guides keep the studied population, endpoint and duration beside each finding.

Reset filters

Guides in this topic

1–12 of 17 guides

Page 1 of 2
Food noise: name the measurement. Appetite rating: Hunger and fullness; Craving questionnaire: A reported eating experience; Food intake: Measured in a defined setting.Research Practice

GLP-1 and “Food Noise”: What Appetite and Craving Studies Actually Measure

GLP-1 and food noise discussions often mix a familiar everyday phrase with several different research outcomes. A person may use food noise to describe persistent thoughts about food.

Updated 2026-11-06 ↗
Hair-loss evidence needs context. Trial event: Defined product and population; Cohort diagnosis: Association in health records; Individual cause: Needs clinical assessment.Research Practice

GLP-1 Drugs and Hair Loss: Reported Events, Weight Change and Causal Uncertainty

GLP-1 and hair loss is a legitimate research question, but reported events do not establish one cause for every person. Product trials, electronic-health-record cohorts and individual experiences provide different kinds of evidence.

Updated 2026-11-06 ↗
Pancreatic evidence: three records. Product warning: Current clinical information; Enzyme result: A laboratory measurement; Clinical event: Diagnosis and adjudication.Research Practice

GLP-1 Drugs and Pancreatitis: Warnings, Enzymes and Adjudicated Events

GLP-1 and pancreatitis discussions need to separate product warnings from laboratory enzyme changes and confirmed clinical events. These records address different questions.

Updated 2026-11-06 ↗
Thyroid evidence is not one claim. Animal finding: Species-specific observations; Human cohort: Association with uncertainty; Product label: Current contraindications.Research Practice

GLP-1 Drugs and Thyroid Cancer: Rodent Warnings and Human Cohort Evidence

GLP-1 and thyroid cancer involves several different evidence questions.

Updated 2026-11-06 ↗
Read three parts of the safety record. Common events: Frequency in a defined study; Serious warnings: Important risk information; Individual assessment: Different clinical circumstances.Research Practice

Ozempic Side Effects in Canada: Common Events, Warnings and Study Context

Ozempic side effects should be read from the current Canadian product monograph and the relevant trial, rather than a generic list for every GLP-1 product.

Updated 2026-11-06 ↗
STEP 8: a direct comparison. Semaglutide arm: A specified trial intervention; Liraglutide arm: A specified trial intervention; Shared context: 68 weeks · adults without diabetes.Research Practice

Semaglutide vs Liraglutide: What the STEP 8 Head-to-Head Trial Shows

Semaglutide vs liraglutide has direct randomized evidence from STEP 8. That is more informative for its particular question than comparing unrelated trials.

Updated 2026-11-06 ↗
gallbladder and bile-duct teaching specimen in a shallow conservation case beside a biliary safety-event folder, in the GLP-1 Drugs and Gallbladder Events research file.Research Practice

GLP-1 Drugs and Gallbladder Events: What the Studies Show

A gallstone, gallbladder inflammation and obstruction of the biliary tract are related outcomes, but they are not interchangeable.

Updated 2026-10-29 ↗
anatomical stomach teaching model beside three short archive tabs Emptying, Symptoms, Diagnosis, in the GLP-1 Drugs and Gastroparesis research file.Research Practice

GLP-1 Drugs and Gastroparesis: Delay, Symptoms and Diagnosis

Delayed gastric emptying is a measured physiological effect. Gastroparesis is a clinical diagnosis that requires more context than a delayed measurement alone.

Updated 2026-10-29 ↗
Detailed monochrome photographic print of an unoccupied DXA scanner, held by archival corners, with Lean mass and Fat mass index slips, in the GLP-1 Weight Loss and Muscle Loss research file.Research Practice

GLP-1 Weight Loss and Muscle Loss: What DXA Can Tell You

A headline about GLP-1 muscle loss may be describing a DXA estimate of lean tissue, the proportion of lost weight classified as lean, or a direct measure of strength.

Updated 2026-10-29 ↗
cutaway eye teaching specimen with a detachable retinal vessel insert illuminated by a desk lamp, in a Retinopathy safety-file setting, in the Semaglutide and Diabetic Retinopathy research file.Research Practice

Semaglutide and Diabetic Retinopathy: Reading the Safety Signal

The semaglutide retinopathy signal arose from a defined complication endpoint in SUSTAIN 6, a cardiovascular trial involving people with type 2 diabetes at high cardiovascular risk.

Updated 2026-10-29 ↗
kidney cross-section teaching specimen with a magnifying glass revealing glomerular detail, on a FLOW case folio, in the Semaglutide and Kidney Disease research file.Research Practice

Semaglutide and Kidney Disease: What the FLOW Trial Found

FLOW studied adults with type 2 diabetes and chronic kidney disease. Its 24% lower hazard concerned a composite of major kidney events and kidney-related or cardiovascular death.

Updated 2026-11-15 ↗
Three-dimensional heart teaching specimen half-exposed from a defined-population archive box, with heading SELECT and a Population evidence tag, in the Semaglutide and Heart Outcomes research file.Research Practice

Semaglutide and Heart Outcomes: The SELECT Population Matters

SELECT tested a cardiovascular question in adults with established cardiovascular disease and overweight or obesity, without diabetes.

Updated 2026-10-29 ↗

Explore the related peptide dossiers

Metabolic Peptides: Trial Outcomes & Safety Evidence | PeptideTwo